MPL and myeloproliferative neoplasm: Importantly, while MPL absence leads to CAMT in humans, MPL expression is impaired but not absent in MPN HSC and HPC and as demonstrated experimentally [61], should give normal HSC and HCP a survival advantage in the presence of a THPO antagonist.